期刊
STROKE
卷 40, 期 3, 页码 S90-S91出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.108.533125
关键词
deferoxamine; ICH; edema; neuroprotection
资金
- National Institutes of Health/National Institute of Neurological Diseases and Stroke [1R01-NS 057127-01A1, 1R01-NS 045754-01A2, 5R01-HL46690-14]
Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations. (Stroke. 2009; 40[suppl 1]: S90-S91.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据